WellThera Co., Ltd.
Teikyo University, Itabashi Campus
2-11-1 Kaga, Itabashi-ku, Tokyo JAPAN, 173-8605
Kazuo Maruyama, Ph.D.（CEO）
Ryo Suzuki, Ph.D.
Daiki Omata, Ph.D.
December 19th, 2018
WellThera is open to exploring innovative collaboration partnerships.
An important feature of BUS-DDS is that it can be utilized in conjunction with therapeutic agents without any need for reformulation. Partnering opportunities exist for therapeutic agents in pre-clinical and clinical development as well as in-market agents.
WellThera is developing platform concepts to increase the therapeutic index; thus, the clinical utility is applicable to a wide range of therapeutic agents from small molecules to nanomedicines.
WellThera aims to partner with clinicians, pharmaceutical companies, and medical device companies that require such technologies.
If you would like to learn more about what BUS-DDS can do for your therapeutic needs, please contact us.